CancerNCT07220343
Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer
A study testing Device and Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App in people with Cancer and Adolescents, run by Stanford University at 1 site in United States.
Trial summary
The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services. Read more about this study
- Who is it for?
- Ages 10 to 25 years
- Conditions the study is for
- Cancer, Adolescents
- What is being tested?
- Device and Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Jan 2025to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- 10-25 years old
- Recent cancer diagnosis (>2 and <18 months since diagnosis)
- Willing to carry smartphone on their person for duration of study participation
- Willing to wear smartwatch for duration of study participation
Who cannot join
- Significant physical or mental disability that prevents completion of study activities
- Lack of proficiency in English or Spanish
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Stanford University
Palo Alto, California, 94304
Olivia Borge, 650-723-9392, oborge@stanford.edu
Victoria Crosgrove, Ph.D.
About this study
Official title: Using Digital Phenotyping to Optimize Psychosocial Risk Screening and Personalized Care: a Pilot Study in Adolescents and Young Adults With Cancer
The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.
- Conditions
- Cancer, Adolescents
- Being tested
- Device, Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App
- Keywords
- Smartphone, Cancer
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DeviceDevice
Participants will wear a wrist-based wearable device for 10 days to passively track physiological data (heart rate, steps, sleep, etc.).
Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone AppBehavioural
Participants will respond to ecological momentary assessments (EMA) via smartphone to actively report on sleep, mood, stress, and eating habits across a 10-day period.
| Study group | Role | What they receive |
|---|---|---|
| Digital Phenotyping Arm | Experimental | All participants (adolescents and young adults with cancer) will receive the digital phenotyping intervention, which includes wearing a smartwatch and using a smartphone-based EMA app over a 10-day period, with psychosocial assessments at baseline, day 10, and 2 months Receives: Device: Device; Behavioral: Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Depressive Symptoms (Beck Depression Inventory - BDI)
The Beck Depression Inventory-II (BDI-II; range 0-63) will be used to measure changes in depressive symptoms among adolescents and young adults over time. Higher scores indicate greater depressive symptom severity.
Measured: Baseline, Day 10, 2 months
Secondary outcomes (7)
Participant Retention Rate (MyPHD App and Wearable Device)
Percentage of participants who remain active in the study through the 2-month follow-up period using the MyPHD app and wearable device.
Measured: Baseline to 2 months
Adherence to EMA Prompts
Mean percentage of EMA prompts completed by participants using the MyPHD mobile app during the 2-month study period. Completion will be assessed via EMA system analytics.
Measured: Baseline to 2 months
Wearable Device Return and Use Rate
Percentage of participants who return and use the wearable device as instructed during the study period. Device use will be tracked through backend device usage logs.
Measured: Baseline to 2 months
Change in Anxiety Symptoms (Beck Anxiety Inventory - BAI)
Measures changes in self-reported anxiety symptoms across the study period.
Measured: Baseline, Day 10, 2 months
Change in PTSD Symptoms (CROPS)
PTSD symptoms are measured using the Child Report of Post-traumatic Symptoms (CROPS) for child participants.
Measured: Baseline
Change in PTSD Symptoms (PCL-5)
PTSD symptoms are measured using the PTSD Checklist for DSM-5 (PCL-5) for general population participants.
Measured: Baseline
Change in Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)
Assesses subjective sleep quality and patterns.
Measured: Baseline, Day 10
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2025
- Study start29 Jan 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Victoria Cosgrove, PhD, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07220343
- Sponsor's protocol ID
- IRB-73748
- Status last verified
- Dec 2025
- First submitted
- 9 Sep 2025
- Last updated
- 30 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Using Digital Phenotyping to Optimize Psychosocial Risk Screening and Personalized Care: a Pilot Study in Adolescents and Young Adults With Cancer
- ClinicalTrials.gov ID
- NCT07220343
- Acronym / sponsor ID
- IRB-73748
- Conditions
- Cancer, Adolescents
- Keywords
- Smartphone, Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Study start
- 29 Jan 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 23 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Digital Phenotyping Arm | Experimental | Device: Device, Behavioral: Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone AppAll participants (adolescents and young adults with cancer) will receive the digital phenotyping intervention, which includes wearing a smartwatch and using a smartphone-based EMA app over a 10-day period, with psychosocial assessments at baseline, day 10, and 2 months |
Who may qualify
- Ages
- 10 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- 10-25 years old
- Recent cancer diagnosis (>2 and <18 months since diagnosis)
- Willing to carry smartphone on their person for duration of study participation
- Willing to wear smartwatch for duration of study participation
Key exclusion criteria (2 listed)
- Significant physical or mental disability that prevents completion of study activities
- Lack of proficiency in English or Spanish
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DeviceParticipants will wear a wrist-based wearable device for 10 days to passively track physiological data (heart rate, steps, sleep, etc.). | Device | Digital Phenotyping Arm |
| Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone AppParticipants will respond to ecological momentary assessments (EMA) via smartphone to actively report on sleep, mood, stress, and eating habits across a 10-day period. | Behavioural | Digital Phenotyping Arm |
Primary outcome
Change in Depressive Symptoms (Beck Depression Inventory - BDI)
Time frame: Baseline, Day 10, 2 months
The Beck Depression Inventory-II (BDI-II; range 0-63) will be used to measure changes in depressive symptoms among adolescents and young adults over time. Higher scores indicate greater depressive symptom severity.
7 secondary outcomes
Participant Retention Rate (MyPHD App and Wearable Device)
Time frame: Baseline to 2 months
Adherence to EMA Prompts
Time frame: Baseline to 2 months
Wearable Device Return and Use Rate
Time frame: Baseline to 2 months
Change in Anxiety Symptoms (Beck Anxiety Inventory - BAI)
Time frame: Baseline, Day 10, 2 months
Change in PTSD Symptoms (CROPS)
Time frame: Baseline
Change in PTSD Symptoms (PCL-5)
Time frame: Baseline
Change in Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)
Time frame: Baseline, Day 10
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Victoria Cosgrove, PhD principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Device and Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App in people with Cancer and Adolescents, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olivia Borge ((650) 723-9392, oborge@stanford.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Depressive Symptoms (Beck Depression Inventory - BDI) (time frame: Baseline, Day 10, 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025.